{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:19:03Z","timestamp":1790659143546,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"am","delay-in-days":373,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.bulcan.2022.08.012","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T09:41:45Z","timestamp":1665394905000},"page":"88-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Maladie de Waldenstr\u00f6m\u00a0: actualit\u00e9s et perspectives en 2022"],"prefix":"10.1016","volume":"110","author":[{"given":"Florian","family":"Bouclet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphn\u00e9","family":"Krzisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Tomowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Laribi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Ysebaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Tournilhac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dartigeas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Lepr\u00eatre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Jondreville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2022.08.012_bib0270","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016\u00a0revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0275","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/sonc.2003.50074","article-title":"Immunophenotypic analysis of Waldenstrom's macroglobulinemia","volume":"30","author":"San Miguel","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0280","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1182\/blood-2003-11-4024","article-title":"Clonotypic IgM V\/D\/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood","volume":"104","author":"Kriangkum","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0285","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/ajh.2830370106","article-title":"Transitions in CD45\u00a0isoform expression indicate continuous differentiation of a monoclonal CD5+ CD11b+ B lineage in Waldenstrom's macroglobulinemia","volume":"37","author":"Jensen","year":"1991","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0290","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3324\/haematol.2012.068478","article-title":"Molecular pathogenesis of Waldenstrom's macroglobulinemia","volume":"97","author":"Braggio","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0295","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood.V100.4.1505.h81602001505_1505_1507","article-title":"Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events","volume":"100","author":"Sahota","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0300","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2005-09-3613","article-title":"Impaired class switch recombination (CSR) in Waldenstrom macroglobulinemia (WM) despite apparently normal CSR machinery","volume":"107","author":"Kriangkum","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0305","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88\u00a0L265P somatic mutation in Waldenstr\u00f6m's macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0310","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.hoc.2018.05.003","article-title":"Genomic Landscape of Waldenstr\u00f6m Macroglobulinemia","volume":"32","author":"Treon","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0315","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88\u00a0mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0320","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","article-title":"Somatic mutations in MYD88\u00a0and CXCR4\u00a0are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia","volume":"123","author":"Treon","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0325","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1158\/1078-0432.CCR-15-0646","article-title":"Genomic landscape of CXCR4\u00a0mutations in Waldenstr\u00f6m Macroglobulinemia","volume":"22","author":"Poulain","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0330","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.2016.71.0814","article-title":"Genomics, signaling, and treatment of Waldenstr\u00f6m macroglobulinemia","volume":"35","author":"Hunter","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0335","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/17474086.2019.1649132","article-title":"CXCR4\u00a0mutations affect presentation and outcomes in patients with Waldenstr\u00f6m macroglobulinemia: a systematic review","volume":"12","author":"Castillo","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0340","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","article-title":"The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88\u00a0and WHIM-like CXCR4\u00a0mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Hunter","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0345","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0350","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.imlet.2016.06.006","article-title":"CXCR4\u00a0signaling in health and disease","volume":"177","author":"Pozzobon","year":"2016","journal-title":"Immunol Lett"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0355","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.16088","article-title":"CXCR4\u00a0mutation subtypes impact response and survival outcomes in patients with Waldenstr\u00f6m macroglobulinaemia treated with ibrutinib","volume":"187","author":"Castillo","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0360","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1158\/1078-0432.CCR-17-0007","article-title":"TP53\u00a0mutation and its prognostic significance in Waldenstrom's macroglobulinemia","volume":"23","author":"Poulain","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0365","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/ajh.26339","article-title":"Cytogenetic and molecular abnormalities in Waldenstr\u00f6m's macroglobulinemia patients: correlations and prognostic impact","volume":"96","author":"Krzisch","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0370","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3324\/haematol.2012.070458","article-title":"Chromosomal aberrations and their prognostic value in a series of 174\u00a0untreated patients with Waldenstr\u00f6m's macroglobulinemia","volume":"98","author":"Nguyen-Khac","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0375","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/bjh.17028","article-title":"6q deletion in Waldenstr\u00f6m macroglobulinaemia negatively affects time to transformation and survival","volume":"192","author":"Garc\u00eda-Sanz","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0380","article-title":"Estimations nationales de l\u2019incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine entre 1990 e t 2018 - Volume 2 - H\u00e9mopathies malignes","author":"Monnereau","year":"2015","journal-title":"Institut de veille sanitaire"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0385","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clml.2013.02.005","article-title":"Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenstr\u00f6m macroglobulinemia","volume":"13","author":"Kyle","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0390","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/annonc\/mdj111","article-title":"Characterization of familial Waldenstrom's macroglobulinemia","volume":"17","author":"Treon","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0395","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2008-06-162768","article-title":"Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma\/Waldenstrom macroglobulinemia patients: a population-based study in Sweden","volume":"112","author":"Kristinsson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0400","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1200\/JCO.19.00394","article-title":"Progression risk stratification of asymptomatic Waldenstr\u00f6m macroglobulinemia","volume":"37","author":"Bustoros","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0405","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.blre.2015.03.001","article-title":"Waldenstr\u00f6m macroglobulinemia: What a hematologist needs to know","volume":"29","author":"Kapoor","year":"2015","journal-title":"Blood Rev"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0410","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.3324\/haematol.2015.133744","article-title":"Bing-Neel syndrome, a rare complication of Waldenstr\u00f6m macroglobulinemia: analysis of 44\u00a0cases and review of the literature. A study on behlf of the French Innovative Leukemia Organization (FILO)","volume":"100","author":"Simon","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0415","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/bjh.16167","article-title":"How we manage Bing-Neel syndrome","volume":"187","author":"Castillo","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0420","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3324\/haematol.2009.017251","article-title":"Pathophysiology of Waldenstr\u00f6m's macroglobulinemia","volume":"95","author":"Stone","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0425","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41375-019-0667-6","article-title":"IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features","volume":"34","author":"Sidana","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0430","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2011-11-388256","article-title":"Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia","volume":"120","author":"Hivert","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0435","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/WCO.0000000000000726","article-title":"Neuropathies and paraproteins","volume":"32","author":"Lunn","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0440","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1182\/blood.2020007092","article-title":"CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapies","volume":"136","author":"Le Cann","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0445","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2008-08-174961","article-title":"International prognostic scoring system for Waldenstrom macroglobulinemia","volume":"113","author":"Morel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0450","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1038\/s41375-019-0431-y","article-title":"A revised international prognostic score system for Waldenstr\u00f6m's macroglobulinemia","volume":"33","author":"Kastritis","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0455","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1053\/sonc.2003.50038","article-title":"Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia","volume":"30","author":"Kyle","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0460","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1200\/JCO.2007.10.9926","article-title":"Primary treatment of Waldenstr\u00f6m macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide","volume":"25","author":"Dimopoulos","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0465","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood-2015-05-647420","article-title":"Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstr\u00f6m macroglobulinemia: final analysis of a phase 2\u00a0study","volume":"126","author":"Kastritis","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0470","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood-2019-121909","volume":"134","author":"Rummel","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0475","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2013-05-503862","article-title":"Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2\u00a0study of the European Myeloma Network (EMN)","volume":"122","author":"Dimopoulos","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0480","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2014-03-566273","article-title":"Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstr\u00f6m's macroglobulinemia","volume":"124","author":"Treon","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0485","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1182\/bloodadvances.2020001963","article-title":"Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstr\u00f6m macroglobulinemia: long-term follow-up","volume":"4","author":"Castillo","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0490","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.20.00555","article-title":"Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenstr\u00f6m macroglobulinemia","volume":"39","author":"Treon","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0495","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","article-title":"Ibrutinib for patients with rituximab-refractory Waldenstr\u00f6m's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3\u00a0trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0500","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3\u00a0trial of ibrutinib plus rituximab in Waldenstr\u00f6m's macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0505","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.21.00838","article-title":"Ibrutinib Plus rituximab versus placebo plus rituximab for Waldenstr\u00f6m's macroglobulinemia: final analysis from the randomized phase III iNNOVATE study","volume":"40","author":"Buske","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0510","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3\u00a0trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0515","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/bloodadvances.2020003895","article-title":"Obinutuzumab and idelalisib in symptomatic patients with relapsed\/refractory Waldenstr\u00f6m macroglobulinemia","volume":"5","author":"Tomowiak","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0520","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S2352-3026(19)30210-8","article-title":"Acalabrutinib monotherapy in patients with Waldenstr\u00f6m macroglobulinemia: a single-arm, multicentre, phase 2\u00a0study","volume":"7","author":"Owen","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0525","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.21.01194","article-title":"Venetoclax in previously treated Waldenstr\u00f6m macroglobulinemia","volume":"40","author":"Castillo","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2022.08.012_bib0265","doi-asserted-by":"crossref","first-page":"e004128","DOI":"10.1136\/jitc-2021-004128","article-title":"CD19-directed chimeric antigen receptor T cell therapy in Waldenstr\u00f6m macroglobulinemia: a preclinical model and initial clinical experience","volume":"10","author":"Palomba","year":"2022","journal-title":"J Immunother Cancer"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122003502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122003502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:37:42Z","timestamp":1757792262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455122003502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0007455122003502"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.08.012","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maladie de Waldenstr\u00f6m\u00a0: actualit\u00e9s et perspectives en 2022","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}